All-cause mortality with current and past use of antidepressants or benzodiazepines after major osteoporotic and hip fracture.
Aged
Aged, 80 and over
Antidepressive Agents
/ administration & dosage
Benzodiazepines
/ administration & dosage
Comorbidity
Databases, Factual
Drug Utilization
/ statistics & numerical data
Female
Follow-Up Studies
Hip Fractures
/ mortality
Humans
Kaplan-Meier Estimate
Male
Netherlands
/ epidemiology
Osteoporotic Fractures
/ mortality
Risk Assessment
/ methods
Antidepressants
Benzodiazepines
Major osteoporotic fracture
Mortality
Osteoporosis
Journal
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
ISSN: 1433-2965
Titre abrégé: Osteoporos Int
Pays: England
ID NLM: 9100105
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
07
09
2018
accepted:
10
01
2019
pubmed:
10
2
2019
medline:
20
8
2019
entrez:
10
2
2019
Statut:
ppublish
Résumé
In the first year, after an osteoporotic fracture of a hip, forearm, upper arm, or spine, the dispensing rates of antidepressants and benzodiazepines increased significantly. After those fractures, recent and past use of antidepressants and benzodiazepines was associated with increased all-cause mortality; current use was not associated with mortality risk. It remains unclear to what extent use of antidepressants and benzodiazepines is associated with mortality risk after a major osteoporotic fracture (MOF). We aimed to study the cumulative use of antidepressants and benzodiazepines during the year after MOF or hip fracture (HF) and whether the use was associated with mortality. A cohort study was performed within the Dutch PHARMO Database Network including all patients aged 65+ with a first record of MOF (hip, humerus, forearm, and clinical vertebral fracture) between 2002 and 2011. Data were analyzed using Cox regression models, adjusted for comorbidities, and concomitant medication use and broken down to index fracture type. A total of 4854 patients sustained a first MOF, of whom 1766 patients sustained a HF. Mean follow-up was 4.6 years, divided in 30-day periods. The cumulative antidepressant and benzodiazepine use during the first year after MOF increased from 10.6 to 14.7% and from 24.0 to 31.4%, respectively. Recent (31-92 days before each follow-up period) and past use (> 92 days before) of antidepressants and benzodiazepines after MOF or HF was associated with an increased all-cause mortality risk but current use (< 30 days before) was not. There is a considerable increase in dispensing rate of antidepressants and benzodiazepines in the first year after a MOF. Recent and past use of these medications was associated with all-cause mortality. The finding that current use was not associated with mortality should be further explored and may probably be explained by the healthy survivor's bias.
Identifiants
pubmed: 30737577
doi: 10.1007/s00198-019-04851-9
pii: 10.1007/s00198-019-04851-9
pmc: PMC6422967
doi:
Substances chimiques
Antidepressive Agents
0
Benzodiazepines
12794-10-4
Types de publication
Journal Article
Langues
eng
Pagination
573-581Subventions
Organisme : ZonMw
ID : 113101007
Références
J Am Geriatr Soc. 2000 Jul;48(7):811-6
pubmed: 10894322
Can J Clin Pharmacol. 2003 Summer;10(2):72-7
pubmed: 12879145
JAMA. 2003 Dec 10;290(22):2942-3
pubmed: 14665654
Int J Geriatr Psychiatry. 2004 May;19(5):472-8
pubmed: 15156549
Am J Addict. 2005 Mar-Apr;14(2):106-23
pubmed: 16019961
J Am Geriatr Soc. 1992 Aug;40(8):787-91
pubmed: 1634722
Osteoporos Int. 2006 Dec;17(12):1726-33
pubmed: 16983459
Int J Clin Pharmacol Ther. 2008 Feb;46(2):72-83
pubmed: 18218287
Osteoporos Int. 2009 Sep;20(9):1499-506
pubmed: 19156348
JAMA. 2009 Feb 4;301(5):513-21
pubmed: 19190316
Sleep Med. 2009 Mar;10(3):279-86
pubmed: 19269892
J Bone Miner Res. 2010 Apr;25(4):866-72
pubmed: 19839771
Drugs Aging. 2009;26(11):963-71
pubmed: 19848441
Arch Intern Med. 2009 Dec 14;169(22):2128-39
pubmed: 20008698
J Clin Psychiatry. 2010 Oct;71(10):1259-72
pubmed: 21062615
J Am Geriatr Soc. 2011 May;59(5):863-8
pubmed: 21517788
Am J Geriatr Pharmacother. 2011 Apr;9(2):109-19
pubmed: 21565710
Can J Psychiatry. 2011 Jun;56(6):377-81
pubmed: 21756452
BMJ. 2011 Aug 02;343:d4551
pubmed: 21810886
J Am Geriatr Soc. 2012 Apr;60(4):616-31
pubmed: 22376048
Osteoporos Int. 2013 Jan;24(1):121-37
pubmed: 22638709
Ann Pharmacother. 2012 Jul-Aug;46(7-8):917-28
pubmed: 22811347
Drug Healthc Patient Saf. 2012;4:93-101
pubmed: 22936860
N Engl J Med. 2013 Jan 24;368(4):351-64
pubmed: 23343064
BMC Med. 2013 Sep 26;11:212
pubmed: 24070457
Laryngoscope. 2014 Mar;124(3):797-802
pubmed: 24155050
JAMA Psychiatry. 2014 Aug;71(8):889-96
pubmed: 24898363
J Bone Miner Res. 2015 Apr;30(4):637-46
pubmed: 25359586
Am J Geriatr Psychiatry. 2015 Oct;23(10):1007-15
pubmed: 25488107
Eur Neuropsychopharmacol. 2015 Oct;25(10):1566-77
pubmed: 26256008
Eur Neuropsychopharmacol. 2015 Nov;25(11):1906-13
pubmed: 26342397
Calcif Tissue Int. 2016 Mar;98(3):235-43
pubmed: 26746477
Ann Pharmacother. 2016 Apr;50(4):253-61
pubmed: 26783360
J Clin Psychiatry. 2016 May;77(5):e566-72
pubmed: 27136668
Clin Interv Aging. 2016 Apr 29;11:489-96
pubmed: 27199553
Lancet. 2016 Aug 20;388(10046):776-86
pubmed: 27423262
J Clin Psychopharmacol. 2016 Oct;36(5):445-52
pubmed: 27580492
PLoS One. 2017 Feb 24;12(2):e0172750
pubmed: 28235069
J Bone Miner Res. 2017 Sep;32(9):1802-1810
pubmed: 28256011
Parkinsonism Relat Disord. 2017 Oct;43:92-96
pubmed: 28797565
Am J Public Health. 1989 Mar;79(3):340-9
pubmed: 2916724
Osteoporos Int. 2018 Feb;29(2):397-407
pubmed: 29170857
Clin Drug Investig. 2018 Jul;38(7):593-602
pubmed: 29589292
Osteoporos Int. 2018 Nov;29(11):2477-2485
pubmed: 30112636
J Clin Epidemiol. 1996 Jan;49(1):115-9
pubmed: 8598504